GLP-1 and Sleep Apnea: What the Zepbound OSA Trial Found

Weight loss has long been recommended for obstructive sleep apnea (OSA), but in late 2024 it became something more specific: tirzepatide (Zepbound) earned an FDA-approved indication to treat moderate to severe OSA in adults with obesity — the first drug of its kind to do so³. Here's what the trial behind that approval actually found.

The trial: SURMOUNT-OSA

The evidence came from SURMOUNT-OSA, a phase 3 randomized, controlled trial specifically designed to test tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity². The trial ran two parallel study groups — one in patients not using positive airway pressure (PAP) therapy, and one in patients who were already using PAP and continued it — to see whether tirzepatide helped both with and without a CPAP machine already in the picture¹.

What it found

Results, published in the New England Journal of Medicine in 2024, showed that tirzepatide substantially reduced the apnea-hypopnea index (AHI, the standard measure of how many times per hour breathing is disrupted during sleep) compared to placebo, in both the PAP and non-PAP groups¹. The effect was large enough, alongside the trial's weight-loss and other secondary outcomes, to support the new FDA indication — the label now states Zepbound is indicated, in combination with a reduced-calorie diet and increased physical activity, "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity"³.

Why weight loss helps OSA, mechanistically

OSA is driven substantially by excess soft tissue around the upper airway — fat deposits in the neck and throat that make the airway more likely to collapse during sleep. Significant weight loss reduces that tissue, which is why weight loss has been standard general advice for OSA for years; what SURMOUNT-OSA demonstrated is that a specific, potent weight-loss drug produces a measurable, statistically robust improvement in the sleep-study metric doctors actually use to diagnose and grade the condition, not just a subjective sense of feeling better¹.

What this means practically

If you have both obesity and diagnosed moderate-to-severe OSA, this is now a formally studied, FDA-approved use of tirzepatide specifically — not an off-label guess. It doesn't replace your CPAP or other PAP therapy outright; the trial's design, testing tirzepatide alongside continued PAP use in one arm, reflects that these are meant to work together for many patients, with your sleep physician deciding whether and when PAP pressure settings or continued use should change based on your improvement¹². This is also relevant to insurance: an FDA-approved indication beyond weight loss alone can change how a plan evaluates coverage, since drugs approved for conditions other than obesity itself are treated differently by many payers than "weight loss" as a stand-alone reason — see our insurance coverage guide for how that plays out more broadly.

Does this apply to semaglutide too?

The FDA-approved OSA indication currently belongs specifically to tirzepatide (Zepbound); semaglutide (Wegovy) does not carry this indication as of this writing. If you have both obesity and diagnosed OSA, that's a genuinely relevant data point when comparing semaglutide vs. tirzepatide with your prescriber, alongside the other factors — cost, tolerability, and availability — that guide should walk through.

The takeaway

A dedicated, well-designed phase 3 trial found tirzepatide meaningfully improved obstructive sleep apnea severity in adults with obesity, whether or not they were also using PAP therapy, and the FDA has approved it specifically for that use. If OSA is part of your health picture, it's worth raising directly with a provider who can weigh it alongside your weight-loss goals — see best GLP-1 provider by need for how a specific health condition should factor into which provider and plan actually fits.